A5081376352- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Cardiomyopathy and Myosin Studies
- Cardiac Imaging and Diagnostics
- COVID-19 Clinical Research Studies
- Acute Myocardial Infarction Research
- Cardiac electrophysiology and arrhythmias
- Healthcare Systems and Public Health
- Long-Term Effects of COVID-19
- Ion channel regulation and function
- Cardiovascular Disease and Adiposity
- Coronary Interventions and Diagnostics
- Cardiac Structural Anomalies and Repair
- Gastrointestinal Tumor Research and Treatment
- Peptidase Inhibition and Analysis
- Emergency and Acute Care Studies
- Thyroid Disorders and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac Health and Mental Health
- Cardiac pacing and defibrillation studies
- Molecular Junctions and Nanostructures
- COVID-19 and healthcare impacts
- Heart rate and cardiovascular health
- Cancer, Lipids, and Metabolism
Humanitas University
2021-2025
IRCCS Humanitas Research Hospital
2021-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2021-2024
Vita-Salute San Raffaele University
1993-2024
San Raffaele University of Rome
2020-2023
IRCCS Ospedale San Raffaele
2018-2023
ORCID
2023
Renal dysfunction (RD) is common in patients with heart failure (HF), however its impact on clinical outcomes tricuspid regurgitation (TR) and HF still debated; therefore, we aimed to assess the of RD this population. All a prevalent or incident diagnosis TR presenting at two centers between January 2020 July 2021 were enrolled, both acute (in-hospitalized patients) chronic settings (outpatient). Patients stratified according degree (Group 1 <30 mL/min (n = 70), Group 2 30-59 123) 3 ≥60 56)....
Cardiovascular sequelae may occur in patients recovered from coronavirus disease 2019 (COVID-19). Recent studies have detected a considerable incidence of subclinical myocardial dysfunction-assessed with speckle-tracking echocardiography-and long-COVID symptoms these patients. This study aimed to define the long-term prognostic role dysfunction and condition COVID-19 pneumonia.We prospectively followed up 110 hospitalized at our institution due pneumonia April 2020 then SARS-CoV-2 infection....
Objective: International guidelines recommend the introduction of sacubitril/valsartan (Entresto) in patients with heart failure (HF) and reduced ejection fraction (EF), who remain symptomatic, despite optimal uptitrated therapy. The purpose following analysis is to verify real-life eligibility for a population suffering from chronic HF, regularly monitored single HF clinic treated according guideline-directed medical therapy (GDMT). Methods: From total 1070 our Clinic between January 2011...
Chest pain is a frequent cause of patient admissions in emergency departments (EDs). Clinical scores can help the management chest patients with an undefined impact on appropriateness hospitalization or discharge when compared to usual care.The aim this study was assess performances HEART score predict 6-month prognostic presenting ED tertiary referral university hospital non-traumatic pain.From 7040 from 1 January 2015 31 December 2017, after applying exclusion criteria (ST-segment...
Abstract Objectives The aim of the present analysis is to evaluate clinical impact chronic total occlusions (CTOs) recanalization in patients with left ventricular (LV) systolic dysfunction. Background According contemporary knowledge, patient selection for percutaneous CTO revascularization not yet standardized. In particular, data on outcomes LV dysfunction undergoing coronary intervention (PCI) are scarce. Methods From a 2,421 consecutive at least one CTO, 436 ejection fraction (EF) ≤45%,...
Ivabradine is a selective and specific inhibitor of I f current. With its pure negative chronotropic action, it recommended by European Society Cardiology American College Cardiology/American Heart Association guidelines in symptomatic heart failure patients (NYHA ≥ 2) with ejection fraction 35% or less, sinus rhythm rate (HR) at least 70 bpm, despite maximally titrated β-blocker therapy. Data supporting this indication mainly derive from the SHIFT study, which ivabradine reduced combined...
Amiodarone is a source of iodine excess that may persist in the body for long time after its withdrawal. The aim present analysis was to evaluate magnitude and long-term course 24-h urinary (UI) excretion patients on antiarrhythmic therapy with amiodarone.
Abstract Background GLP1-ra have demonstrated substantial cardiovascular (CV) benefits in diabetic and, more recently, non-diabetic patients, however their use heart failure (HF) patients is still limited. Purpose To evaluate real-word eligibility to a cohort of HF patients. Methods Demographic and clinical data from evaluated at single center unit August 1st 2021 November 29th 2023 were automatically retrieved the electronic health record (EHR). Patients deemed eligible based on (1) absence...
Abstract Purpose. Amiodarone is a source of excess iodine that may induce thyroid dysfunction. The aim the present analysis was to evaluate magnitude and time course 24-hr urinary excretion its potential relationship with disorders in patients on antiarrhythmic prophylaxis amiodarone. Methods. function were evaluated 67 chronic amiodarone therapy. All clinically biochemically euthyroid before starting treatment followed up by 6-month measurements plasma TSH levels. Results. Since initiation,...
Abstract Aims Cardiovascular sequelae may occur in patients recovered from COVID-19. Recent studies have detected a considerable incidence of subclinical myocardial dysfunction – assessed with speckle-tracking echocardiography and long-COVID symptoms these patients. This study aimed to define the long-term prognostic role condition COVID-19 pneumonia. Methods Results We prospectively followed-up 110 hospitalized at our Institution due pneumonia April 2020 then SARS-CoV-2 infection. A 6-month...
Abstract Background Guidelines recommend betablockers (BB) as first line therapy in symptomatic patients with hypertrophic cardiomyopathy (HCM). A secondary role the therapeutic algorithm is assigned to non-dihydropyridine calcium channel blockers (ND-CCB). Since no randomized comparison trials between two drugs have been made so far, aim of present analysis was evaluate prognostic impact BB and ND-CCB a cohort HCM, either obstructive or not. Methods From 1434 diagnosis HCM included French...